Stratosvir Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $331K

  • Investors
  • 5

Stratosvir General Information

Description

Developer of immunotherapy intended to improve the clinical treatment of solid tumors and their metastases. The company engineers a cancer-killing virus to be used intravenously to deliver medicinal payloads within the tumor to stimulate and reprogram the immune system to attack and destroy cancer, enabling cancer patients to improve their immune system in their fight for effective, safe, non-toxic cancer treatments that increase the quality of life and survival.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 46-54 High Street
  • Ingatestone CM4 9DW
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 46-54 High Street
  • Ingatestone CM4 9DW
  • England, United Kingdom

Stratosvir Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Stratosvir Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 06-Jun-2024 $331K Completed Generating Revenue
2. Accelerator/Incubator 14-Jul-2023 Completed Generating Revenue
1. Early Stage VC 01-Jan-2020 Completed Generating Revenue
To view Stratosvir’s complete valuation and funding history, request access »

Stratosvir Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view Stratosvir’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Stratosvir Patents

Stratosvir Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4453007-A1 Improved vaccinia virus vectors Pending 24-Dec-2021
GB-202119008-D0 Improved vaccinia virus vectors Pending 24-Dec-2021
GB-2614309-A Improved vaccinia virus vectors Pending 24-Dec-2021
JP-2025503515-A Improved vaccinia virus vectors Pending 24-Dec-2021
US-20250302997-A1 Improved vaccinia virus vectors Pending 24-Dec-2021 A61K48/0058
To view Stratosvir’s complete patent history, request access »

Stratosvir Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Stratosvir Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Proven Connect Impact Investing Minority
Stevenage Bioscience Catalyst Accelerator/Incubator
Cancer Research Technology Venture Capital Minority
Deep Science Ventures Venture Capital Minority
O2h Ventures Venture Capital Minority
To view Stratosvir’s complete investors history, request access »

Stratosvir FAQs

  • When was Stratosvir founded?

    Stratosvir was founded in 2020.

  • Where is Stratosvir headquartered?

    Stratosvir is headquartered in Ingatestone, United Kingdom.

  • What is the size of Stratosvir?

    Stratosvir has 6 total employees.

  • What industry is Stratosvir in?

    Stratosvir’s primary industry is Drug Discovery.

  • Is Stratosvir a private or public company?

    Stratosvir is a Private company.

  • What is the current valuation of Stratosvir?

    The current valuation of Stratosvir is .

  • What is Stratosvir’s current revenue?

    The current revenue for Stratosvir is .

  • How much funding has Stratosvir raised over time?

    Stratosvir has raised $331K.

  • Who are Stratosvir’s investors?

    Proven Connect, Stevenage Bioscience Catalyst, Cancer Research Technology, Deep Science Ventures, and O2h Ventures have invested in Stratosvir.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process